Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,057.00+0.27%ETH$2,410.70+0.05%GOLD$4,300.40-1.99%OIL$102.01-0.41%
Smart Investors Daily
DR

NASDAQ · DRMA

Dermata Therapeutics, Inc.

Healthcare · Biotechnology

$1.13

Up+$0.02 (+1.77%)

Updated Sep 16, 2026, 10:37 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.9M
P/E ratio
-0.32
Dividend yield
0.00%
52-week range
$0.95 – $6.22
Volume
37.19K
Avg. volume
196.69K

Price performance

DRMA price history

1M range · 20 trading sessions · Daily adjusted prices

DRMA closed at $1.13 after 20 trading sessions, down 20.98% for the selected period.

Last close
$1.13
Period change
-20.98%
Period low
$1.13
Period high
$1.72
Daily close
View OHLC price history
DRMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.16$1.1868$1.0601$1.1337.19K
Sep 14, 2026$1.18$1.2699$1.15$1.1517.83K
Sep 11, 2026$1.23$1.23$1.16$1.1926.73K
Sep 10, 2026$1.21$1.225$1.18$1.2016.42K
Sep 9, 2026$1.24$1.28$1.21$1.2118.41K
Sep 8, 2026$1.22$1.3115$1.21$1.2551.18K
Sep 4, 2026$1.23$1.2591$1.2011$1.2140.56K
Sep 3, 2026$1.28$1.3687$1.21$1.23101.9K
Sep 2, 2026$1.31$1.31$1.25$1.2855.13K
Sep 1, 2026$1.27$1.31$1.25$1.3017.45K
Aug 31, 2026$1.30$1.33$1.27$1.2961.67K
Aug 28, 2026$1.47$1.58$1.34$1.34104.63K
Aug 27, 2026$1.59$1.59$1.46$1.4688.12K
Aug 26, 2026$1.70$1.72$1.59$1.6176.42K
Aug 25, 2026$1.65$1.72$1.50$1.72196.01K
Aug 24, 2026$1.43$1.63$1.41$1.63218.33K
Aug 21, 2026$1.38$1.47$1.36$1.42230.39K
Aug 20, 2026$1.49$1.49$1.36$1.3899.23K
Aug 19, 2026$1.45$1.58$1.42$1.47143.92K
Aug 18, 2026$1.42$1.47$1.40$1.43141.64K

Latest DRMA news

The latest Smart Investors Daily articles mentioning DRMA.

Stock researchCompany · Overview

DRMA research

Overview

Company profile and research snapshot.

Company profile

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
DRMA recent ratings
DateFirmRatingTarget
Aug 21, 2025Maxim GroupBuy—
May 21, 2025Maxim GroupBuy—
Aug 21, 2024Maxim GroupBuy—
Mar 23, 2023Maxim GroupBuy—
Sep 21, 2021Brookline CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories

The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, greater patient awareness and demand for safer, non-antibiotic treatments. Advanced therapies—including topical ivermectin, azelaic acid, minocycline foam, modified-release doxycycline, biologics and microbiome-based solutions—are reshaping care. Growth across North America, Europe and Asia-Pacific is also supported by dermatology R&D, innovative drug delivery and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By